SEC EDGAR · Company announcement
ENTG: Company disclosure · Other company developments
Filed 8-K for an event or period dated 2026-11-08. Company disclosure; Other company developments.
Follow ENTG- Became public
- Nov 10, 2026, 7:31 AM EST
- Event / period date
- Nov 8, 2026
- Collected
- Nov 10, 2026, 12:12 PM EST
Why this is connected
This filing identifies ENTEGRIS INC as the issuer of the security. The company's SEC identifier connects it to ENTG.
Source evidence
Read the source excerpt or record
Item 7.01 Regulation FD Disclosure. On November 9, 2026, Entegris, Inc. (the “Company”) hosted its 2026 Capital Markets Day (the “Capital Markets Day”). At the event, members of management presented information on, among other things, the Company’s long-term growth strategy, long-term financial model and capital allocation framework. The event was webcast live on the Company’s investor relations website at investor.entegris.com. A copy of the press release the Company issued on November 9, 2026 about the Capital Markets Day is furnished as Exhibit 99.1 to this Current Report on Form 8-K. A copy of the presentation materials used at the event is furnished as Exhibit 99.2. The presentation materials are also available on the Company’s investor relations website. Information on or accessible through the Company’s website is not incorporated by reference into this Current Report on Form 8-K. The information in this Item 7.01, including Exhibits 99.1 and 99.2, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. It shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. The furnishing of the information in this Item 7.01 is not an admission as to the materiality of such information. Item 8.01 Other Events. Share Repurchase Program . On November 8, 2026, the Board of Directors of the Company (the “Board”) authorized a share repurchase program under which the Company may repurchase up to $500 million of its outstanding common stock. The program has no expiration date. Repurchases may be made
Congressional trading in ENTG
These disclosures provide context. Their presence does not establish a link between a trader and the event.
- Sep 9, 2026$100K–$250K
Rep. April McClain Delaney (D-MD-6)
$100K–$250K · Traded Aug 25, 2026 · disclosed Sep 9, 2026 · Dependent
Committee overlap: Science - Aug 3, 2026$1K–$15K
Rep. April McClain Delaney (D-MD-6)
$1K–$15K · Traded Jul 30, 2026 · disclosed Aug 3, 2026 · Dependent
Committee overlap: ScienceTraded 5 days before earnings - Aug 3, 2026$1K–$15K
Rep. April McClain Delaney (D-MD-6)
$1K–$15K · Traded Jul 8, 2026 · disclosed Aug 3, 2026 · Dependent
Committee overlap: Science - Jul 7, 2026$1K–$15K
Rep. April McClain Delaney (D-MD-6)
$1K–$15K · Traded Jun 8, 2026 · disclosed Jul 7, 2026 · Dependent
Committee overlap: Science - Jul 7, 2026$1K–$15K
Rep. April McClain Delaney (D-MD-6)
$1K–$15K · Traded Jun 5, 2026 · disclosed Jul 7, 2026 · Dependent
Committee overlap: Science - Jun 5, 2026$1K–$15K
Rep. April McClain Delaney (D-MD-6)
$1K–$15K · Traded May 21, 2026 · disclosed Jun 5, 2026 · Dependent
Committee overlap: Science - Jun 5, 2026$1K–$15K
Rep. April McClain Delaney (D-MD-6)
$1K–$15K · Traded May 8, 2026 · disclosed Jun 5, 2026 · Dependent
Committee overlap: Science - Jun 5, 2026$1K–$15K
Rep. April McClain Delaney (D-MD-6)
$1K–$15K · Traded May 7, 2026 · disclosed Jun 5, 2026 · Dependent
Committee overlap: Science
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.